Dance Biopharm's Adagio inhaled insulin passes PhI/II; ANI, Sofgen team up for oral soft gel cardiovascular treatment;

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Dance Biopharm welcomed Phase I/II clinical data for its Adagio inhalable insulin candidate for Type 1 diabetes. Release

> ANI Pharmaceuticals ($ANIP) teamed up with Sofgen Pharmaceuticals to develop an oral soft gel to treat cardiovascular diseases. Release

> Researchers at the RIKEN Center for Emergent Matter Science and the University of Tokyo are leading the development of a nanomed that uses energy levels to control the delivery of a therapeutic payload. Article

> TherapeuticsMD began a Phase I study of its estradiol VagiCap to deliver hormone supplements to treat vulvar and vaginal atrophy. Release

> XstalBio launched its CentuRecon delivery tech for highly concentrated biologic drugs prepared in minutes rather than hours. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.